The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2023 | PROSPECT: neoadjuvant CRT vs FOLFOX in locally advanced rectal cancer
Olatunji Alese, MD, Emory Winship Cancer Institute, Atlanta, GA, discusses findings from the Phase III PROSPECT trial (NCT01515787) of neoadjuvant chemoradiation (CRT) versus neoadjuvant FOLFOX chemotherapy, followed by total mesorectal excision (TME) in patients with locally advanced rectal cancer (LARC). The study demonstrated clinical benefit for neoadjuvant FOLFOX, where patients can avoid chemoradiation and subsequently receive surgery. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
